News >

Dose-Dense Adjuvant Chemotherapy Shows Potential in Endometrial Cancer

Jason Harris
Published: Friday, Sep 22, 2017

Liron Kogan, MD

Liron Kogan, MD
Dose-dense chemotherapy could be a superior option for adjuvant treatment of endometrial cancer compared with standard chemotherapy, according to findings from investigators with Segal Cancer Center at Jewish General Hospital in Montreal.

Until Sep 27, 2016, 29 patients progressed and 24 deaths occurred in the standard therapy cohort, compared with 11 progressions and 9 deaths in the [dose-dense] cohort. At 42 months, which represents the median follow-up in the experimental cohort, twice as many patients in the standard group progressed (18 vs 9) and more than twice as many died (17 vs 7).
Kogan L, Laskov I, Amajoud Z, et al. Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecol Oncol. 2017;147(1):30-35. doi:10.1016/j.ygyno.2017.07.134.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication